Portfolio

Visceral Leishmaniasis Portfolio

By 2020, DNDi aims to deliver from its VL-specific portfolio:

• Potentially a safe, effective, low-cost, and short-course oral combination treatment
• A new treatment for PKDL that is shorter course and better tolerated than current options
• Treatment options for HIV/VL co-infected patients
• A new first-line treatment regimen for visceral leishmaniasis in Latin America

 

Cutaneous Leishmaniasis Portfolio

By 2020, DNDi aims to deliver from its CL-specific portfolio:

• A safe, effective, and shorter-course treatment for cutaneous leishmaniasis

 

The current portfolio for both visceral and cutaneous leishmaniasis includes:

	Research Aminopyrazoles Booster H2L CGH VL Series 1 Daiichi-Sankyo LH2L DNDI-5421 & DNDI-5610 Leish H2L Leish L205 Series Screening
	Translation CpG-D35 DNDI-6148 DNDI-0690 DNDI-5561 GSK3186899/DDD853651 – GSK3494245/DDD1305143 New CL Combination Therapies
	Development MF/PM Combination for Africa New treatments for HIV/VL New treatments for PKDL New VL treatments Latin America
	Implementation SSG&PM New VL Treatments – Asia

 

For more details on each project, see DNDi‘s Global Portfolio